Haw Par Corporation Limited (HAWPY)
USD 28.64
(0.0%)
USD 28.64
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 64.01 Million SGD | -59.87% |
| 2022 | 159.49 Million SGD | 37.25% |
| 2021 | 116.2 Million SGD | -6.5% |
| 2020 | 124.28 Million SGD | -36.96% |
| 2019 | 197.16 Million SGD | 136.82% |
| 2018 | 83.25 Million SGD | -40.24% |
| 2017 | 139.31 Million SGD | 1.68% |
| 2016 | 137.01 Million SGD | -1.61% |
| 2015 | 139.25 Million SGD | 24.36% |
| 2014 | 111.97 Million SGD | 15.95% |
| 2013 | 96.57 Million SGD | 14.25% |
| 2012 | 84.52 Million SGD | 8.62% |
| 2011 | 77.81 Million SGD | -8.24% |
| 2010 | 84.8 Million SGD | 1.58% |
| 2009 | 83.48 Million SGD | -7.69% |
| 2008 | 90.43 Million SGD | -17.06% |
| 2007 | 109.03 Million SGD | -7.98% |
| 2006 | 118.5 Million SGD | 25.79% |
| 2005 | 94.2 Million SGD | 7.03% |
| 2004 | 88.01 Million SGD | 33.43% |
| 2003 | 65.96 Million SGD | -8.34% |
| 2002 | 71.96 Million SGD | 28.16% |
| 2001 | 56.15 Million SGD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 15.63 Million SGD | -13.47% |
| 2024 Q2 | 15.63 Million SGD | 0.0% |
| 2023 Q1 | 13.93 Million SGD | 22.62% |
| 2023 Q4 | 18.06 Million SGD | 0.0% |
| 2023 FY | 64.01 Million SGD | -59.87% |
| 2023 Q2 | 13.93 Million SGD | 0.0% |
| 2023 Q3 | 18.06 Million SGD | 29.65% |
| 2022 Q4 | 11.36 Million SGD | 0.0% |
| 2022 FY | 159.49 Million SGD | 37.25% |
| 2022 Q1 | 10.32 Million SGD | -9.98% |
| 2022 Q2 | 20.94 Million SGD | 102.86% |
| 2022 Q3 | 11.36 Million SGD | -45.73% |
| 2021 Q1 | 6.29 Million SGD | 269.88% |
| 2021 Q4 | 11.46 Million SGD | 89.54% |
| 2021 Q3 | 6.05 Million SGD | -50.88% |
| 2021 Q2 | 12.31 Million SGD | 95.62% |
| 2021 FY | 116.2 Million SGD | -6.5% |
| 2020 Q1 | 10.26 Million SGD | -33.42% |
| 2020 Q3 | -3.3 Million SGD | -116.5% |
| 2020 FY | 124.28 Million SGD | -36.96% |
| 2020 Q4 | -3.7 Million SGD | -12.32% |
| 2020 Q2 | 19.99 Million SGD | 94.8% |
| 2019 FY | 197.16 Million SGD | 136.82% |
| 2019 Q4 | 15.41 Million SGD | -74.67% |
| 2019 Q3 | 60.87 Million SGD | -35.63% |
| 2019 Q2 | 94.57 Million SGD | 259.65% |
| 2019 Q1 | 26.29 Million SGD | 19.69% |
| 2018 Q1 | 23.68 Million SGD | 21.24% |
| 2018 Q4 | 21.97 Million SGD | -63.72% |
| 2018 Q3 | 60.55 Million SGD | -28.82% |
| 2018 Q2 | 85.08 Million SGD | 259.3% |
| 2018 FY | 83.25 Million SGD | -40.24% |
| 2017 FY | 139.31 Million SGD | 1.68% |
| 2017 Q4 | 19.53 Million SGD | -55.06% |
| 2017 Q3 | 43.46 Million SGD | -21.69% |
| 2017 Q2 | 55.5 Million SGD | 166.61% |
| 2017 Q1 | 20.81 Million SGD | 2.92% |
| 2016 Q4 | 20.22 Million SGD | -55.33% |
| 2016 FY | 137.01 Million SGD | -1.61% |
| 2016 Q3 | 45.28 Million SGD | -11.26% |
| 2016 Q2 | 51.03 Million SGD | 149.23% |
| 2016 Q1 | 20.47 Million SGD | -11.7% |
| 2015 FY | 139.25 Million SGD | 24.36% |
| 2015 Q4 | 23.18 Million SGD | -37.89% |
| 2015 Q3 | 37.33 Million SGD | -40.54% |
| 2015 Q2 | 62.78 Million SGD | 293.46% |
| 2015 Q1 | 15.95 Million SGD | 64.33% |
| 2014 Q3 | 28.22 Million SGD | -54.25% |
| 2014 Q4 | 9.71 Million SGD | -65.59% |
| 2014 Q1 | 12.36 Million SGD | 48.94% |
| 2014 FY | 111.97 Million SGD | 15.95% |
| 2014 Q2 | 61.68 Million SGD | 398.98% |
| 2013 Q1 | 9.43 Million SGD | 33.14% |
| 2013 Q3 | 24.06 Million SGD | -56.06% |
| 2013 Q2 | 54.76 Million SGD | 480.3% |
| 2013 FY | 96.57 Million SGD | 14.25% |
| 2013 Q4 | 8.3 Million SGD | -65.51% |
| 2012 Q1 | 8.5 Million SGD | -27.3% |
| 2012 Q3 | 22.6 Million SGD | -51.28% |
| 2012 Q4 | 7.08 Million SGD | -68.63% |
| 2012 FY | 84.52 Million SGD | 8.62% |
| 2012 Q2 | 46.38 Million SGD | 445.59% |
| 2011 Q4 | 11.69 Million SGD | 22.17% |
| 2011 Q1 | 7.53 Million SGD | -24.54% |
| 2011 Q2 | 49.01 Million SGD | 550.8% |
| 2011 FY | 77.81 Million SGD | -8.24% |
| 2011 Q3 | 9.57 Million SGD | -80.47% |
| 2010 Q2 | 43.71 Million SGD | 400.29% |
| 2010 Q4 | 9.98 Million SGD | -55.39% |
| 2010 FY | 84.8 Million SGD | 1.58% |
| 2010 Q3 | 22.37 Million SGD | -48.81% |
| 2010 Q1 | 8.73 Million SGD | 8.08% |
| 2009 Q1 | 9.77 Million SGD | 0.0% |
| 2009 Q4 | 8.08 Million SGD | -65.85% |
| 2009 Q3 | 23.67 Million SGD | -43.57% |
| 2009 Q2 | 41.95 Million SGD | 329.23% |
| 2009 FY | 83.48 Million SGD | -7.69% |
| 2008 FY | 90.43 Million SGD | -17.06% |
| 2007 FY | 109.03 Million SGD | -7.98% |
| 2006 FY | 118.5 Million SGD | 25.79% |
| 2005 FY | 94.2 Million SGD | 7.03% |
| 2004 FY | 88.01 Million SGD | 33.43% |
| 2003 FY | 65.96 Million SGD | -8.34% |
| 2002 FY | 71.96 Million SGD | 28.16% |
| 2002 Q2 | 13.85 Million SGD | 0.0% |
| 2002 Q4 | 15.19 Million SGD | 0.0% |
| 2001 FY | 56.15 Million SGD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AstraZeneca PLC | 8.19 Billion USD | 99.219% |
| Bristol-Myers Squibb Company PFD CONV 2 | 17.24 Billion USD | 99.629% |
| CSPC Pharmaceutical Group Limited | 7.01 Billion USD | 99.088% |
| Clarus Therapeutics Holdings, Inc. | -39.73 Million USD | 261.107% |
| Novartis AG | 9.76 Billion USD | 99.345% |
| PT Kalbe Farma Tbk. | 3625.13 Billion USD | 99.998% |